Correlation of Serum Adropin Levels with Risk Factors of Cardiovascular Disease in Hemodialysis Patients
Publication: Metabolic Syndrome and Related Disorders
Volume 19, Issue Number 7
Abstract
Background: Many preclinical studies have shown that adropin has physiological effects such as regulating glucose, lipid, and energy metabolism, protecting endothelial cells and antiatherosclerosis. Our aim is to explore whether adropin is correlated with risk factors of cardiovascular disease (CVD) in hemodialysis (HD) patients.
Methods: We recruited 170 HD patients and 120 healthy controls. The serum adropin concentration and clinical characteristics were measured.
Results: The serum adropin concentration in HD patients was significantly lower than that in healthy controls and which in HD patients with CVD or diabetes mellitus (DM) was significantly lower than that in patients without CVD or DM. The correlation analysis showed that serum adropin levels were correlated negatively with Age, CVD history, DM history, C-reactive protein, type B natriuretic peptide, phosphorus, intact parathyroid hormone, carotid artery plaque amount and carotid intima-media thickness (CIMT), left ventricular septal thickness (LVSTd), and left ventricular posterior wall thickness, whereas it was correlated positively with albumin, hemoglobin, serum creatinine and Kt/V, and ejection fraction value. Partial correlation analysis verified that serum adropin levels were correlated negatively with CIMT, and multiple linear regression analysis revealed that low serum adropin levels may be one independent predictors of CIMT. However, the partial correlation analysis and multiple linear regression analysis did not identify the significant correlation between serum adropin levels and LVSTd.
Conclusions: Our study revealed that serum adropin level is significantly correlated with risk factors of CVD and low serum adropin levels may be a potential predictor of CVD in HD patients.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Aoki J, Ikari Y. Cardiovascular disease in patients with end-stage renal disease on hemodialysis. Ann Vasc Dis 2017;10:327–337.
2. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003;63:S105–S110.
3. Ahmadmehrabi S, Tang WHW. Hemodialysis-induced cardiovascular disease. Semin Dial 2018;31:258–267.
4. Marczuk N, Cecerska-Heryc E, Jesionowska A, et al. Adropin—Physiological and pathophysiological role. Postepy Hig Med Dosw 2016;70:981–988.
5. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 2013;380:73–81.
6. Kutlu O, Altun O, Dikker O, et al. Serum adropin levels are reduced in adult patients with nonalcoholic fatty liver disease. Med Princ Pract 2019;28:463–469.
7. Shahjouei S, Ansari S, Pourmotabbed T, et al. Potential roles of adropin in central nervous system: Review of current literature. Front Mol Biosci 2016;3:25.
8. Hu W, Chen L. Association of serum adropin concentrations with diabetic nephropathy. Mediators Inflamm 2016;2016:6038261.
9. Li L, Xie W, Zheng XL, et al. A novel peptide adropin in cardiovascular diseases. Clin Chim Acta 2016;453:107–113.
10. Sato K, Yamashita T, Shirai R, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci 2018;19:1293.
11. Wu L, Fang J, Yuan X, et al. Adropin reduces hypoxia/reoxygenation-induced myocardial injury via the reperfusion injury salvage kinase pathway. Exp Ther Med 2019;18:3307–3314.
12. Thapa D, Stoner MW, Zhang M, et al. Adropin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-PDK4 signaling pathway. Redox Biol 2018;18:25–32.
13. Zheng J, Liu M, Chen L, et al. Association between serum adropin level and coronary artery disease: A systematic review and meta-analysis. Cardiovasc Diagn Ther 2019;9:1–7.
14. Wang B, Xue Y, Shang F, et al. Association of serum adropin with the presence of atrial fibrillation and atrial remodeling. J Clin Lab Anal 2019;33:e22672.
15. Yosaee S, Soltani S, Sekhavati E, et al. Adropin-a novel biomarker of heart disease: A systematic review article. Iran J Public Health 2016;45:1568–1576.
16. Liu F, Zhang X, Qi H, et al. Correlation of serum magnesium with cardiovascular risk factors in maintenance hemodialysis patients—A cross-sectional study. Magnes Res 2013;26:100–108.
17. Kaluzna M, Pawlaczyk K, Schwermer K, et al. Adropin and irisin: New biomarkers of cardiac status in patients with end-stage renal disease? A preliminary study. Adv Clin Exp Med 2019;28:347–353.
18. Kaluzna M, Hoppe K, Schwermer K, et al. Adropin and irisin levels in relation to nutrition, body composition, and insulin resistance in patients with end-stage renal disease on chronic hemodialysis and peritoneal dialysis. Pol Arch Med Wewn 2016;126:474–482.
19. Grzegorzewska AE, Niepolski L, Mostowska A, et al. Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients. Life Sci 2016;160:41–46.
20. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metabol 2012;97:3783–3791.
21. Zang H, Jiang F, Cheng X, et al. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocrine J 2018;65:685–691.
22. Choi HN, Yim JE. Plasma adropin as a potential marker predicting obesity and obesity-associated cancer in Korean patients with type 2 diabetes mellitus. J Cancer Prev 2018;23:191–196.
23. Palizban AA, Yazdani AH, Jahanbani-Ardakani H. Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case-control study from Isfahan, Iran. Arch Physiol Biochem 2019;125:1–4.
24. Dabrowski FA, Jarmuzek P, Gondek A, et al. First and third trimester serum concentrations of adropin and copeptin in gestational diabetes mellitus and normal pregnancy. Ginekol Polska 2016;87:629–634.
25. Oruc CU, Akpinar YE, Dervisoglu E, et al. Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome. Clin Chem Lab Med 2017;55:139–144.
Information & Authors
Information
Published In
Metabolic Syndrome and Related Disorders
Volume 19 • Issue Number 7 • September 2021
Pages: 401 - 408
PubMed: 34042533
Copyright
Copyright 2021, Mary Ann Liebert, Inc., publishers.
History
Published online: 2 September 2021
Published in print: September 2021
Published ahead of print: 26 May 2021
Topics
Authors
Authors' Contributions
F.L., B.C., and H.Q. designed experiments. X.Z., Y.W., H.Q., Y.G., H.W., M.L., S.Z., J.S., X.S., W.L., S.M., and A.Z. conducted the experiments. F.L. and B.C. analyzed data. F.L., B.C., and H.Q. prepared the article.
Author Disclosure Statement
No conflicting financial interests exist.
Funding Information
This study was supported by the grants from the Academic Leader Training Plan of Health System of Pudong New District of Shanghai, China (PWRd2019-13 to F.L.), Science, Technology and Economic Committee of Pudong New District of Shanghai, China (PKJ2017-Y19 to F.L.), and Leading Talent Training Plan of Health System of Pudong New District of Shanghai, China (PWRl2019-08 to H.Q.).
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.